A Randomised Trial of Bevacizumab in Ovarian Cancer
ICON7 is a randomised (1:1 ratio), 2 arm, multi-centre, Gynecologic Cancer InterGroup (GCIG) open-label phase III trial designed to evaluate the safety and efficacy of adding bevacizumab, to standard chemotherapy (carboplatin and paclitaxel), in patients with advanced epithelial ovarian or primary peritoneal cancer.
Bevacizumab (Avastin®) is a recombinant humanised anti-VEGF (anti - Vascular Endothelial Growth Factor) monoclonal antibody. It is a new type of treatment that acts by interfering with the development of tumour blood vessels.
The ICON7 trial is closed to recruitment as of Monday 16th February 2009, no further participants can join the trial.